VIS confirms Highnoon’s long-term A+ rating

April 7, 2026 (MLN):  Highnoon Laboratories Limited (PSX:HINOON) has successfully reaffirmed its strong credit ratings, which reflects the company’s solid market position and robust financial management.

VIS Credit Rating Company Limited (VIS) maintained Highnoon’s entity ratings at A+ for long term and a short term rating of A1 with a ‘Positive’ outlook, signaling good credit quality and strong liquidity.

The reaffirmed rating emphasizes Highnoon’s resilience within a medium-to-low risk pharmaceutical sector, supported by consistent domestic demand and regulatory pricing stability.

Despite ongoing industry-wide pressures and regional export disruptions, the company has maintained steady revenue growth through a well-diversified product portfolio and prudent pricing strategies.

 Notably, its top five products contribute around 26% of total sales, reflecting low revenue concentration risk.

Highnoon’s conservative capital structure and strong internal capital generation have enabled active deleveraging and reduced dependence on external borrowings, resulting in favorable gearing metrics.

The company’s liquidity reserves and projected operational cash flows are expected to comfortably support planned investments in manufacturing expansion, further reinforcing its financial stability.

Looking ahead, the ratings remain underpinned by Highnoon’s ability to manage the financial implications of new debt mobilization for planned facilities, positioning the company for sustainable growth and enhanced market capacity.

Established in 1984, Highnoon Laboratories is a leading pharmaceutical company in Pakistan, engaged in the manufacturing, importing, and marketing of a wide range of therapeutic products.

The company’s registered office and manufacturing facilities are located on Multan Road, Lahore. Highnoon produces treatments for respiratory, inhalation, cardiology, and diabetes-related conditions, ranking as the 13th largest pharmaceutical company in the country with a market share of 2.55%.

Through its wholly owned subsidiary, Curexa Health Private Limited, Highnoon also produces antibiotics, particularly cephalosporins.

Curexa’s cGMP-compliant facilities manufacture sterile powders for injections, oral suspension powders, and capsules for both local and international markets, covering therapeutic areas such as respiratory, gastroenterology, urology, gynecology, and pediatrics.

Copyright Mettis Link News